Aakaar Medical approves ESOP 2026, hikes share capital
Aakaar Medical Technologies Limited approved the Aakar Medical Technologies Employee Stock Option Plan 2026 for 11.33 lakh options and increased authorized share capital to ₹15.40 crore. The options are exercisable into equity shares of ₹10 each, with a vesting period of at least 12 months. Both approvals are subject to shareholder consent.
*this image is generated using AI for illustrative purposes only.
Aakaar Medical Technologies Limited has approved the Aakar Medical Technologies Employee Stock Option Plan 2026, enabling the grant of 11,33,825 stock options to eligible employees, subject to shareholder approval. The Board of Directors also sanctioned an increase in the company's authorized share capital from ₹15 crore to ₹15.40 crore. These decisions were taken during a board meeting held on May 25, 2026, under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The ESOP 2026 is established in accordance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The options are available for grant to employees of the company and its subsidiaries in one or more tranches. These options are exercisable into not exceeding 11,33,825 fully paid-up equity shares, each with a face value of ₹10.
The exercise price per option will not be less than the face value of one equity share and will not exceed the fair market price as on the date of grant. The Board or the Nomination and Remuneration Committee retains the authority to determine the exact price within this range. The committee may also facilitate a cashless exercise of options for employees, subject to applicable laws.
Vesting for the options will commence after a minimum period of 12 months from the date of grant. The specific period within which the vested options may exercised will be determined by the Board or the Nomination and Remuneration Committee in accordance with the scheme's terms. Currently, no options have been vested, exercised, or lapsed, and no money has been realized from the exercise of options.
Concurrently, the Board approved an increase in the authorized share capital to accommodate the new issuance. The capital is being raised from ₹15,00,00,000 divided into 1,50,00,000 equity shares of ₹10 each, to ₹15,40,00,000 divided into 1,54,00,000 equity shares of ₹10 each. This change requires a consequent amendment to the capital clause of the Memorandum of Association and is subject to shareholder approval at the ensuing Annual General Meeting.
Key Details of Aakar Employee Stock Option Scheme-2026
| Particulars | Details |
|---|---|
| Total Options Available | 11,33,825 |
| Shares Covered | 11,38,825 equity shares of ₹10 each |
| Pricing Formula | Not less than face value; not exceeding fair market price as on date of grant |
| Vesting Period | Not less than 12 months from date of grant |
| Options Vested | NIL |
| Options Exercised | NIL |
| Money Realized | NIL |
| Options Lapsed | NIL |
Historical Stock Returns for Aakaar Medical Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.09% | +4.37% | +6.62% | +2.21% | +4.00% | +4.00% |
How will the dilution of equity from the issuance of over 11 lakh shares impact existing shareholders' value?
What specific retention and performance metrics will the Nomination and Remuneration Committee use to determine the vesting schedules?
How does the company plan to fund the cashless exercise of options, and what impact might this have on its cash flow?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
